

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

In re PATENT Application of)
Tohru Natsume)
Application No. 10/581,969)
Filed: June 7, 2006)
National Stage of)
International Application No. PCT/JP04/18179)
International Filing Date: December 7, 2004)

For: NOVEL INTERACTION BETWEEN PROTEINS, AND THERAPEUTIC AGENT FOR
DISUSE MUSCULAR ATROPHY OR METHOD ASSOCIATED WITH DISUSE
MUSCULAR ATROPHY TAKING ADVANTAGE OF NOVEL INTERACTION

**SUBMISSION OF SEQUENCE LISTING AND
STATEMENT UNDER 37 CFR 1.821**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted in accordance with 37 CFR 1.821(e) is a computer readable form
containing copy of the Sequence Listing as *txt format file.

STATEMENT UNDER 37 CFR 1.821(f)


Pursuant to 37 CFR 1.821(f), I the undersigned attorney for Applicants, hereby state
that the sequence listing information recorded in computer readable form is identical to the
written on paper sequence listing filed on April 26, 2007, and includes no new matter.

Respectfully submitted,

Roberts, Mlotkowski & Hobbes P.C.

Dated: February 27, 2008

By:


Stanislaus Aksman

Registration No. 28,562

Customer No. 25570

Roberts Mlotkowski & Hobbes P.C.
P.O. Box 10064
McLean, VA 22102
Telephone: (703) 677-3003